Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 101 to 110 of 123 total matches.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
is teratogenic.
Women with reproductive potential and their male
partners should use effective contraception ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Encorafenib (Braftovi) for Metastatic Colorectal Cancer
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
contraceptives. It should not be coadministered with
other drugs that also prolong the QT interval.4
Table 1 ...
The FDA has approved the oral kinase inhibitor
encorafenib (Braftovi – Pfizer), in combination with
the epidermal growth factor receptor (EGFR) inhibitor
cetuximab (Erbitux), for treatment of adults with
metastatic colorectal cancer (CRC) with a BRAF
V600E mutation. Encorafenib was approved in 2018
for use with the mitogen-activated kinase (MEK)
inhibitor binimetinib (Mektovi) for treatment of
unresectable or metastatic melanoma with a BRAF
V600E or V600K mutation.
Ofatumumab (Kesimpta) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
potential
should use effective contraception while receiving
ofatumumab and for 6 months after stopping ...
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has...
Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
partners should use effective contraception
during treatment with pemigatinib and for 1 week after ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has received accelerated approval from
the FDA for treatment of adults with previously
treated, unresectable, locally advanced or metastatic
cholangiocarcinoma with fibroblast growth factor
receptor 2 (FGFR2) fusions or other rearrangements.
Pemigatinib is the first drug to be approved in the US
for this indication.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
use effective contraception during treatment with fam-trastuzumab deruxtecan and for at least 7 months ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Cenobamate (Xcopri) for Focal Seizures
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
that
are metabolized by these isozymes, including other
ASDs and oral contraceptives.
Cenobamate is a moderate ...
The FDA has approved cenobamate (Xcopri – SK Life
Science) for oral treatment of partial-onset (focal)
seizures in adults.
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
Phexxi - A Nonhormonal Contraceptive Gel ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
effective contraception while
taking ozanimod and for 3 months after stopping it.
Ozanimod ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
Talicia - A 3-Drug Combination for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
and inducer of
CYP3A.
Talicia can decrease the effectiveness of hormonal
contraceptives. Women who ...
The FDA has approved a fixed-dose combination
of omeprazole, amoxicillin, and rifabutin (Talicia –
RedHill) for treatment of Helicobacter pylori infection
in adults. Talicia is the first rifabutin-based product to
be approved for this indication.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Mar 23, 2020 (Issue 1594)
: Drospirenone (Slynd) — A New Progestin-Only
Oral Contraceptive
In our article on Slynd (Med Lett Drugs Ther ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.IBS
is classified according to the predominant bowel
symptom as IBS with constipation (IBS-C), IBS with
diarrhea (IBS-D), mixed type (IBS-M), or unclassified
(IBS-U). Alterations in the microbiome, stress
responses, sensory and motor function of the gut,
and host genetic factors may be contributing factors.
Since the exact cause of IBS is unknown, the goal of
treatment is symptom control.